EDMONTON, Alberta, March 15, 2018 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V:CZO) (“Ceapro” or the “Company”), a
growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and
cosmetic industries, announced today that Gilles Gagnon M.Sc., MBA, Ceapro’s President and Chief Executive Officer, will present at The
Wall Street Investor Forum 26th Annual Investor Conference in New York City at The University Club of NYC on Thursday, March 22,
2018 at 10:20 a.m. ET.
As a part of his presentation, Mr. Gagnon, will provide a corporate overview and an update on the Company’s
de-risked cosmeceuticals business. Ceapro recently launched its proprietary line of cosmeceutical products through the acquisition
of Quebec-based company, JuventeDC Inc. and has begun commercialization of its line of skin-care products. As part of the Company’s
long-term strategic vision, Ceapro is also developing its two value drivers, the pharmaceutical grade active ingredients
avenanthramides and beta glucan, into different formulations to enable the Company’s transition into other sectors including
nutraceuticals and pharmaceuticals.
In addition to the presentation, management will be available to participate in one-on-one meetings with
qualified members of the investor community who are registered to attend the conference. Qualified members of the investment
community are invited to attend at no cost. For more information, please visit the conference website.
A live webcast of the presentation will be available on the Company's web site (www.ceapro.com). The webcast replay will be available approximately two hours after the
presentation ends and will be archived for one year following the presentation.
About Ceapro Inc.
Ceapro Inc. is a Canadian biotechnology company involved in the development of proprietary extraction technology
and the application of this technology to the production of extracts and “active ingredients” from oats and other renewable plant
resources. Ceapro adds further value to its extracts by supporting their use in cosmeceutical, nutraceutical, and therapeutics
products for humans and animals. The Company has a broad range of expertise in natural product chemistry, microbiology,
biochemistry, immunology and process engineering. These skills merge in the fields of active ingredients, biopharmaceuticals and
drug-delivery solutions. For more information on Ceapro, please visit the Company’s website at www.ceapro.com.
For more information contact:
Jenene Thomas
Jenene Thomas Communications, LLC
Investor Relations and Corporate Communications Advisor
T (US): 908-938-1475
E: jenene@jtcir.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of
the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release
